GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
Alnylam Pharmaceuticals has expanded its longstanding commercial partnership with GENESIS Pharma to include four Nordic markets: Denmark, Finland, Norway, and Sweden. This expansion adds to the existing coverage of 13 Southeast European markets, bringing GENESIS Pharma’s total coverage to 24 countries in Europe for Alnylam’s RNAi therapeutics.
Key figures
- New markets count
- 4
- Existing markets count
- 13
- Total countries covered
- 24
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.